Xcout Intel
miRecule, Inc.
miRecule, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, focused on developing RNA therapeutics.
Subscribe to see miRecule, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
miRecule, Inc. at a glance
miRecule, Inc. is a biotechnology company headquartered in United States. It has raised at least $12M across the 3 funding rounds on record. Its most recent funding round, Seed, raised $7M in May 2021. Xcout tracks 1 named person at miRecule, Inc., including Anthony Saleh (CEO).
miRecule, Inc. leadership
- Anthony SalehCEO
miRecule, Inc. funding rounds
At least $12M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $7M | 3 named | |
| Seed | $3.5M | 1 named | |
| SEC Form D filing | $1.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
miRecule, Inc. competitors
A few of miRecule, Inc.'s closest competitors — see the full list of competitors and alternatives →
Ceptur Therapeutics, Inc. is a private biotechnology company headquartered in Hillsborough, New Jersey, focused on developing targeted oligonucleotide therapeutics.
Georgiamune Inc. is a clinical-stage science and discovery biotechnology company headquartered in Gaithersburg, Maryland, operating within the BioHealth Capital Region.
Rgenta Therapeutics, Inc. is a biotechnology research company headquartered in Woburn, Massachusetts, that focuses on unlocking the therapeutic potential of disease-relevant RNA targets.
Remix Therapeutics, Inc. is a biotechnology company headquartered in Watertown, Massachusetts. The company specializes in developing novel therapies that alter RNA processing to address serious diseases.
Mitotherapeutix, LLC is a biotechnology company that develops small interfering RNA (siRNA) based therapeutics targeting difficult disease pathways. The company focuses on modulating mitochondrial metabolic activity by inhibiting a negative gene regulator to treat a wide array of diseases.
Get miRecule, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on miRecule, Inc. in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access